Race Oncology Ltd. AI Stock Analysis
Want to see AU:RAC full AI Analyst Report?
Race Oncology Ltd. (RAC) AI Stock Analysis
Race Oncology Ltd.
(ASX:RAC)
The score is driven primarily by persistent losses, zero current revenue, and substantial cash burn. The debt-free balance sheet provides some support, but weak technical momentum and an unfavorable loss-based valuation keep the overall score low.
Race Oncology Ltd. (RAC) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 308.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 86.24K
- Price to Earnings (P/E)
- -25.4
- Beta (1Y)
- 0.06
- Revenue Growth
- ―
- EPS Growth
- -125.09%
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Race Oncology Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated prote...
Race Oncology Ltd. Financial Statement Overview
Summary
Financial performance is very weak overall: the income statement and cash flow show persistent losses, no current revenue, and substantial cash burn. A debt-free, equity-funded balance sheet is the main offset.
Income Statement
18Very NegativeBalance Sheet
68PositiveCash Flow
24Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 6.04M | 4.00M | 3.13M | 707.81K |
| Gross Profit | -281.20K | -281.31K | 5.41M | 2.22M | -281.20K | 426.61K |
| EBITDA | -12.15M | -12.15M | -4.43M | -14.20M | -12.78M | -11.63M |
| Net Income | -11.09M | -11.09M | -4.79M | -13.82M | -9.92M | -11.20M |
Balance Sheet | ||||||
| Total Assets | 38.09M | 38.09M | 17.49M | 20.23M | 26.64M | 37.52M |
| Cash, Cash Equivalents and Short-Term Investments | 34.29M | 34.29M | 13.67M | 17.19M | 21.52M | 33.54M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.64M | 1.64M | 1.48M | 1.92M | 1.15M | 1.42M |
| Stockholders Equity | 36.45M | 36.45M | 16.01M | 18.31M | 25.49M | 36.11M |
Cash Flow | ||||||
| Free Cash Flow | -8.25M | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
| Operating Cash Flow | -8.25M | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
| Investing Cash Flow | -3,142 | -3,142 | 0 | 0 | 7.90M | 0 |
| Financing Cash Flow | 28.87M | 28.87M | 1.06M | 5.21M | -1.28M | 30.51M |
Race Oncology Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAC, the sentiment is Neutral. The current price of 1.57 is above the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.77, and below the 200-day MA of 2.23, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.75 is Neutral, neither overbought nor oversold. The STOCH value of 67.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RAC.
Race Oncology Ltd. Peers Comparison
Overall Rating
AU:TLX53Neutral
AU:CU645Neutral
AU:RAD42Neutral
AU:IMU39Underperform- AU:RAC39Underperform
AU:IMM38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:TLX | 53Neutral | AUD 4.62B | 96.23 | 7.24% | ― | 26.66% | 179.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:CU6 | 45Neutral | AUD 677.14M | -6.26 | -51.15% | ― | ― | -44.83% |
| AU:RAD | 42Neutral | AUD 18.84M | -0.26 | -144.24% | ― | -23.82% | 12.36% |
| AU:IMU | 39Underperform | AUD 19.78M | -0.11 | -414.10% | ― | ― | -2.15% |
| AU:RAC | 39Underperform | AUD 308.81M | -25.44 | -36.95% | ― | ― | -125.09% |
| AU:IMM | 38Underperform | AUD 36.85M | -0.46 | -98.86% | ― | ― | -27.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:RAC | Race Oncology Ltd. | 1.57 | -1.88 | -54.35% | |
| AU:IMU | Imugene Ltd | 0.04 | -0.26 | -88.00% | |
| AU:IMM | Immutep Ltd | 0.03 | -0.26 | -91.07% | |
| AU:TLX | Telix Pharmaceuticals Ltd. | 13.58 | -0.62 | -4.37% | |
| AU:CU6 | Clarity Pharmaceuticals Ltd. | 1.81 | -2.24 | -55.30% | |
| AU:RAD | Radiopharm Theranostics Limited | 0.01 | -0.01 | -56.52% |
Race Oncology Ltd. Corporate Events
Racura Oncology Sets Date and Venue for 2026 In-Person AGM
Racura Oncology Ltd has scheduled its 2026 Annual General Meeting to be held in person at the State Library of New South Wales in Sydney on 23 November 2026 at 12.00 pm AEDT. Shareholders are encouraged to register attendance in advance via an online...
Racura Oncology strengthens RC220 clinical pipeline on solid cash base
Racura Oncology reported a cash balance of $30.7 million at 30 September 2026, with 80% of quarterly spending directed to research and development and drug manufacturing, placing the company in a strong position to fund committed activities into mid-...
Racura Oncology Cleared to Escalate RC220 Dose in HARNESS-1 Trial
Racura Oncology has received clearance from the Safety Review Committee to escalate the dose of its investigational drug RC220 to 100 mg/m2 in the Phase 1 HARNESS-1 trial for EGFR-mutant non-small cell lung cancer. The committee found no dose-limitin...
Racura Oncology Sets AGM Date and Deadline for Director Nominations
Racura Oncology has scheduled its Annual General Meeting for 12:00 pm AEDT on 23 November 2026 at the State Library of New South Wales in Sydney. The meeting will include the re-election and appointment of directors, with written nominations for boar...
Race Oncology director Daniel Tillett lifts indirect shareholding
Race Oncology director Daniel Tillett has increased his indirect shareholding in the company through Nucleics Pty Ltd, where he is the sole director and shareholder. The on-market purchase of 23,000 fully paid ordinary shares on 24 and 25 September 2...
Racura Oncology CEO Restructures Shareholdings With No Change in Overall Stake
Racura Oncology has disclosed a change in CEO Dr Daniel Tillett’s shareholding structure that involves the on-market sale of personally held RAC shares and the corresponding on-market purchase of RAC shares by Nucleics Pty Ltd, a company solely owned...
Racura Oncology Data Boosts MYC-Targeted Cancer Program and IP Position
Racura Oncology will present new preclinical data on its RC220 program at the 2026 Frontiers in Cancer Science Conference in Singapore, in partnership with the American Association for Cancer Research. The poster details how the (E,E)-bisantrene isom...
Racura Oncology to Host Adelaide Investor Briefing on Clinical Pipeline
Racura Oncology Ltd has invited investors to a briefing in Adelaide on 30 September 2026, where Managing Director and CEO Dr Daniel Tillett will provide updates on the company’s clinical programs. The event aims to give existing and prospective share...
Racura Oncology Issues New Long-Dated Employee Options
Racura Oncology Ltd has issued 1,579,963 unquoted options under its employee incentive scheme, each exercisable at $3.05 and expiring on 30 June 2030. These options, which are subject to transfer restrictions and will not be quoted on the ASX until t...
Racura Oncology Opens Korean Sites for RC220 Cardioprotective Cancer Trial
Racura Oncology has opened its first Korean site at Ewha Womans University Seoul Hospital for patient enrolment in the CPACS Phase 1 trial of RC220 with doxorubicin in advanced solid tumours. Additional sites at Severance Hospital and Samsung Medical...
Racura Oncology details strengthened corporate governance framework
Racura Oncology Ltd has formally outlined its corporate governance framework, confirming that its board of directors is responsible for overseeing the company’s operations on behalf of shareholders and for maintaining high standards of accountability...
Race Oncology lodges ASX corporate governance statement for FY26
Race Oncology Ltd. has filed its corporate governance statement and Appendix 4G with the ASX for the financial year ended 30 June 2026, providing a centralised key to its governance disclosures. The submission confirms that the statement is current a...
Racura Oncology posts deeper annual loss but lifts net asset backing
Racura Oncology Ltd, formerly known as Race Oncology Limited, reported a sharp deterioration in its financial performance for the year ended 30 June 2026, with revenue from ordinary activities falling 22.2% to $613,291. The loss after tax attributabl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026